Piramal Pharma Limited announced its un-audited financial results for the third quarter (Q3) and nine months (9M) ended December 31, 2025. The company reported consolidated revenue from operations of ₹2,140 crore for Q3 FY26, a 3% decrease compared to ₹2,204 crore in Q3 FY25. For the nine-month period, revenue stood at ₹6,117 crore, down 4% from ₹6,397 crore in the same period last year. Consolidated EBITDA for Q3 FY26 was ₹239 crore, a 32% decline from ₹350 crore in Q3 FY25. The EBITDA margin compressed to 11% from 16% year-on-year. Profit After Tax (PAT) after exceptional items stood at a loss of ₹136 crore for Q3 FY26, compared to a profit of ₹4 crore in the prior year. For the nine-month period, PAT was a loss of ₹317 crore, versus a loss of ₹62 crore in 9M FY25. The company cited inventory destocking in a key product, slower early-stage order inflows due to inconsistent recovery in US biopharma funding, and regulatory delays in inhalation anesthesia as reasons for the revenue impact. However, Piramal Pharma noted early signs of recovery with a pickup in Requests for Proposals (RFPs) and order inflows since October 2025, driven by improved biopharma funding and increased M&A activities in the US. Key business highlights include the acquisition of Kenalog® for an upfront consideration of US$35 million and a contingent consideration of up to US$65 million. The Complex Hospital Generics (CHG) business saw revenue growth of 2% in Q3 FY26, while Piramal Consumer Healthcare (PCH) reported a robust 20% revenue growth, driven by power brands and e-commerce sales. Piramal Pharma Limited will be hosting a conference call for investors and analysts on January 29, 2026, from 9:30 AM to 10:15 AM IST to discuss its Q3 and 9M FY26 results.
